Celltrion, Inc. (KRX:068270)
178,200
+200 (0.11%)
At close: Sep 29, 2025
Celltrion Revenue
Celltrion had revenue of 961.46B KRW in the quarter ending June 30, 2025, with 9.91% growth. This brings the company's revenue in the last twelve months to 3.75T, up 40.59% year-over-year. In the year 2024, Celltrion had annual revenue of 3.56T with 63.45% growth.
Revenue (ttm)
3,748.95B
Revenue Growth
+40.59%
P/S Ratio
10.46
Revenue / Employee
1.40B
Employees
2,680
Market Cap
39.21T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,557.30B | 1,380.87B | 63.45% |
Dec 31, 2023 | 2,176.43B | -107.54B | -4.71% |
Dec 31, 2022 | 2,283.97B | 390.57B | 20.63% |
Dec 31, 2021 | 1,893.40B | 44.29B | 2.39% |
Dec 31, 2020 | 1,849.12B | 720.66B | 63.86% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
Sam Chun Dang Pharm. | 215.10B |
LigaChem Biosciences | 148.28B |
Celltrion News
- 6 days ago - Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence - GuruFocus
- 6 days ago - South Korea's Celltrion unit buys Eli Lilly's production facility for $330M - Seeking Alpha
- 5 months ago - Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value - GuruFocus
- 5 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing ... - GuruFocus
- 5 months ago - Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement - Business Upturn
- 6 months ago - Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025 - Financial Post
- 7 months ago - Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada - Financial Post
- 10 months ago - FDA approves Celltrion's biosimilar of J&J's Stelara - Seeking Alpha